EUCTR2017-002326-21-ES进行中（未招募）1 期
An Open-label, Multicenter, Phase 2 trial of selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and refractory multiple myeloma - GEM-SELIBORDARA
Fundación PETHEMA0 个研究点目标入组 62 人开始时间: 2018年2月12日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient is, in the investigator’s opinion, willing and able to comply with the protocol requirements.
- •2. Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- •3. Patient must be at least 18 years of age.
- •4. Patient must have a confirmed diagnosis of symptomatic multiple myeloma and measurable secretory disease, defined as either serum monoclonal protein = 0,5 g/dL or urine monoclonal (light chain) protein = 200 mg/24 hours. For patients in whom measurable disease is performed by serum FLC, the involved FLC should be ? 10 mg/dL, with an abnormal serum FLC ratio.
- •5. Patients must have an ECOG performance status of 0, 1 or 2.
- •6. All patients must have received prior treatment with proteasome inhibitors and immunomodulators: A minimum of 2 consecutive cycles of proteasome inhibitors and immunomodulators are required.
- •7. Patients must have received = 3 prior lines of therapy and be refractory to the last line of therapy, or
- •a. Be double refractory to proteasome inhibitors and immunomodulatory drugs on their most recent therapy, regardless of the prior number lines of therapy.
- •b. Patients were thought to be refractory if they had progressed on or within 60 days of treatment with bortezomib and/or lenalidomide.
- •8. Patient has the following laboratory values within 14 days before Baseline visit (Day 1 of Cycle 1, before study drug administration): Platelet count = 75 x109/L, hemoglobin = 8.0g/dl and absolute neutrophil count (ANC) = 1.5 x 109/L; lower values may be accepted if clearly are due to bone marrow involvement by multiple myeloma (ANC = 1.0 x 109/L and platelets = 50 x109/L if bone marrow infiltration > 60%). Patients receiving hematopoietic growth factor support, including erythropoietin (EPO), darbepoetin, granulocyte-colony stimulating factor (G-CSF) may continue to do so.
- •9. Corrected serum calcium < 14mg/dl.
- •10. Aspartate transaminase (AST): = 2.5 x the upper limit of normal, alanine transaminase (ALT): = 2.5 x the upper limit of normal, and total bilirrubin: = 2.0 x the upper limit of normal.
- •11. Calculated creatinine clearance = 20 ml per minute, calculated using the formula of Cockroft and Gault:
- •(140-Age) • Mass (kg)/(72 • creatinine mg/dL)
- •Multiply times 0.85 if the patient is female, or CrCl >20 mL/min as measured by 24-hour urine collection.
- •12. Women of childbearing potential must be practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies: eg, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods: condom with spermicidal foam/gel/film/cream/suppository; male partner steritilization (the vasectomized partner should be the sole partner for that subject); true abstinence (when this is in line with the preferred and usual lifestyle of the subject) during and after the study (6 months after the last dose of any component of the treatment regimen).
- •13. A woman of childbearing potential must have a negative serum pregnancy test at screening within 10-14 days and 24 hours before commencing treatment. Females of reproductive potential must commit either to abstain continuously from heterosexual sexua
排除标准
- •1. Subject has received selinexor or daratumumab therapies previously.
- •2. Patients who are refractory to daratumumab or CD38 targeting antibody.
- •3. Subject has a diagnosis of plasma cell leukemia, primary amyloidosis, monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM).
- •4. Subject has previously received autologous stem cell transplantation within 12 weeks before Cycle Day 1, or has received other anti-myeloma treatment within 2 weeks before Cycle 1 Day 1 (with the exception of an emergency use of a short course [maximum 4 days] of corticosteroids).
- •5. Subject who had previously received allogeneic stem cell transplantation within the last year or even latter if they have evidence of graft versus host disease.
- •6. Subject has peripheral neuropathy or neuropathic pain grade 2 or higher, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.
- •7. Subject has had any prior or concurrent invasive malignancy (other than myeloma) within 5 years of study start except adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, localized prostate adenocarcinoma diagnosed = 3 years and without evidence of biochemical failure, or other cancer for which the subject has undergone potentially curative therapy and has no evidence of that disease for = 5 years.
- •8. Subject has had radiation therapy within 28 days of Cycle 1 Day 1.
- •9. Subject has meningeal involvement of multiple myeloma.
- •10. Subject has known severe chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume [FEV] in 1 second <60% of predicted normal), persistent asthma, or a history of severe asthma within 5 years. Subjects with known or suspected COPD or asthma must have a FEV test during screening.
- •11. Subjects have known moderate or severe persistent asthma within the past 2 years (see Appendix 8: National Heart, Lung, and Blood Institute (NHLBI) table of asthma severity), or currently has uncontrolled asthma of any classification. (Note that subjects who currently have controlled intermittent asthma or controlled mild ersistene asthma are allowed in the study).
- •12. Unstable cardiovascular function:
- •a. Symptomatic ischemia, or
- •b. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), or
- •c. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class = 3, or
- •d. Myocardial infarction (MI) within 3 months.
- •13. Patients with uncontrolled hypertension.
- •14. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose.
- •15. Subject is known to be seropositive for history of human immunodeficiency virus (HIV) or hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg] or antibodies to hepatitis B surface and core antigens [anti HBs and anti-HBc, respectively]) or hepatitis C (anti-HCV antibody positive or HCV-RNA quantitation positive).
- •16. Patients with any GI dysfunction who are unable to swallow tablets, or any GI dysfunction that could interfere with absorption of study treatment.
- •17. Serious psychiatric or medical conditions that, in the opinion of the investigator, could interfere
研究者
相似试验
进行中（未招募）
不适用
An open-label, multicenter phase II trial of Sunitinib for patients with chemo-refractory metastatic gastric cancerChemorefractory metastatic adenocarcinoma of stomach, esophagogastric junction and lower esophagus (Barrett carcinoma)MedDRA version: 8.1Level: LLTClassification code 10017758Term: Gastric cancerEUCTR2006-000476-33-DEJohannes-Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik50
Unknown
2 期
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple MyelomaRefractory Multiple MyelomaNCT03589222PETHEMA Foundation62
已完成
1 期
A clinical trial to study safety and effects of P276-00 in combination with radiation in patients with recurrent and /or locally advanced head and neck cancerCTRI/2009/091/000115Piramal Life Sciences23
进行中（未招募）
1 期
A MULTICENTER TRIAL OF A NEW CUSTOMIZED DOSING (RATIONAL ADJUSTMENT OF DOSE TO REDUCE ADVERSE REACTIONS RADAR” DOSING) OF NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL RECURRENT CANCER PATIENTSOvarian, fallopian tube or primary peritoneal recurrent cancerMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: SOCClassification code 10038604Term: Reproductive system and breast disordersSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2018-003736-77-DEIstituto di Ricerche Farmacologiche Mario Negri IRCCS105
未知
2 期
A phase 2 study, multicenter, open label trial of R1415 (erlotinib hydrochloride) in patients with advanced, metastatic or recurrent non-small cell lung cancer.(JO16565)Advanced or metastatic or recurrent non-small cell lung cancerJPRN-jRCT2080220076Chugai Pharmaceutical Co., Ltd.